Incyte Corp to Discuss Opzelura (ruxolitinib) Cream FDA Approval Call Summary - Thomson StreetEvents

Incyte Corp to Discuss Opzelura (ruxolitinib) Cream FDA Approval Call Summary

Incyte Corp to Discuss Opzelura (ruxolitinib) Cream FDA Approval Call Summary - Thomson StreetEvents
Incyte Corp to Discuss Opzelura (ruxolitinib) Cream FDA Approval Call Summary
Published Sep 22, 2021
18 pages (9534 words) — Published Sep 22, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of INCY.OQ conference call or presentation 22-Sep-21 12:00pm GMT

  
Brief Excerpt:

...FDA approved Opzelura (ruxolitinib) cream for short-term and non-continuous chronic treatment of mild to moderate AD in non-immunocompromised patients 12 years of age and older, whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable....

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
Incyte Corp
Ticker
INCY.OQ
Time
12:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

Incyte Corp Q3 2021 Earnings Call Summary – 2021-11-02 – US$ 54.00 – Edited Brief of INCY.OQ earnings conference call or presentation 2-Nov-21 12:00pm GMT

Incyte Corp Q3 2021 Earnings Call Transcript – 2021-11-02 – US$ 54.00 – Edited Transcript of INCY.OQ earnings conference call or presentation 2-Nov-21 12:00pm GMT

Incyte Corp GVHD Update Call: Approval in cGVHD and Syndax Collaboration Summary – 2021-09-27 – US$ 54.00 – Edited Brief of INCY.OQ conference call or presentation 27-Sep-21 2:00pm GMT

Incyte Corp GVHD Update Call: Approval in cGVHD and Syndax Collaboration Transcript – 2021-09-27 – US$ 54.00 – Edited Transcript of INCY.OQ conference call or presentation 27-Sep-21 2:00pm GMT

Incyte Corp to Discuss Opzelura (ruxolitinib) Cream FDA Approval Call Transcript – 2021-09-22 – US$ 54.00 – Edited Transcript of INCY.OQ conference call or presentation 22-Sep-21 12:00pm GMT

Incyte Corp at Morgan Stanley Global Healthcare Conference (Virtual) Transcript – 2021-09-13 – US$ 54.00 – Edited Transcript of INCY.OQ presentation 13-Sep-21 3:45pm GMT

Incyte Corp Q2 2021 Earnings Call Summary – 2021-08-03 – US$ 54.00 – Edited Brief of INCY.OQ earnings conference call or presentation 3-Aug-21 12:00pm GMT

Incyte Corp Q2 2021 Earnings Call Transcript – 2021-08-03 – US$ 54.00 – Edited Transcript of INCY.OQ earnings conference call or presentation 3-Aug-21 12:00pm GMT

Incyte Corp at Guggenheim Biopharma's Next Decade Virtual Conference Transcript – 2021-06-28 – US$ 54.00 – Edited Transcript of INCY.OQ presentation 28-Jun-21 3:00pm GMT

Incyte Corp at Goldman Sachs Global Healthcare Conference (Virtual) Transcript – 2021-06-08 – US$ 54.00 – Edited Transcript of INCY.OQ presentation 8-Jun-21 12:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Incyte Corp to Discuss Opzelura (ruxolitinib) Cream FDA Approval Call Summary" Sep 22, 2021. Alacra Store. May 16, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Incyte-Corp-to-Discuss-Opzelura-ruxolitinib-Cream-FDA-Approval-Call-B14991878>
  
APA:
Thomson StreetEvents. (2021). Incyte Corp to Discuss Opzelura (ruxolitinib) Cream FDA Approval Call Summary Sep 22, 2021. New York, NY: Alacra Store. Retrieved May 16, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Incyte-Corp-to-Discuss-Opzelura-ruxolitinib-Cream-FDA-Approval-Call-B14991878>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.